We show that USP7 activity is essential for leukemic cells and targeting of USP7 might provide an alternative therapeutic approach for leukemia, also for the most aggressive subtypes of AML that harbor mutations in TP53. This evidence concerns the gene TP53 and acute myeloid leukemia.